Combining optical coherence tomography with visual field data to rapidly detect disease progression in glaucoma: a diagnostic accuracy study

David F Garway-Heath,¹* Haogang Zhu,^{1,2,3} Qian Cheng,³ Katy Morgan,⁴ Chris Frost,⁴ David P Crabb,² Tuan-Anh Ho¹ and Yannis Agiomyrgiannakis⁵

¹National Institute for Health Research (NIHR) Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK

²Division of Optometry and Visual Science, School of Health Sciences, City, University of London, London, UK

 ³School of Computer Science and Engineering, Beihang University, Beijing, China
⁴Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK
⁵Detionst representative

⁵Patient representative

*Corresponding author david.garway-heath@moorfields.nhs.uk

Declared competing interests of authors: David Garway-Heath has received consulting fees from Aerie Pharmaceuticals Inc., Alcon, Alimera Sciences, Inc., Allergan, CenterVue Inc., Pfizer Inc., Quark Pharmaceuticals, Quethera Ltd, F Hoffman-La Roche Ltd, Santen Pharmaceutical Co., Ltd, Santhera Pharmaceuticals and Sensimed AG, a grant from Pfizer Inc. and lecture fees from Heidelberg Engineering Ltd, Santen Pharmaceutical Co., Ltd and Topcon Corporation and his institution has received equipment Ioans from Carl Zeiss Meditec AG, Heidelberg Engineering Ltd and Optovue, Inc. He is also a member of the HTA Clinical Evalution and Trials Board. David P Crabb has received lecture fees from Allergan, F Hoffman-La Roche Ltd and Santen Pharmaceutical Co., Ltd and consulting fees from Allergan and his institution has received unrestricted research funds from Allergan, CenterVue Inc., Novartis UK, F Hoffman-La Roche Ltd and Santen Pharmaceutical Co., Ltd. He has also provided expert testimony for the Driving and Vehicle Licensing Agency. Tuan-Anh Ho has received salary from the National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology and consultancy fees from Allergan. David Garway-Heath, David P Crabb, Qian Cheng and Haogang Zhu have a patent application filed for ANSWERS (a method of data analysis evaluated in this work).

Published January 2018 DOI: 10.3310/hta22040

Plain English summary

Imaging technology to detect glaucoma disease progression Health Technology Assessment 2018; Vol. 22: No. 4 DOI: 10.3310/hta22040

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Plain English summary

G laucoma is an eye disease in which progressive damage to the optic nerve causes loss of vision in parts of the eye's field of vision and may eventually lead to blindness. The loss of vision is measured with the visual field (VF) test. The measurements are, however, very variable, so that identifying whether or not an eye continues to lose vision is challenging. The damage to the nerve can also be measured with imaging techniques, one of which is called optical coherence tomography (OCT), which measures the thickness of the layer of nerve fibres entering the optic nerve. It is possible that combining measurements from the VF and OCT results in less variability, making it easier to identify worsening of glaucoma.

In this work we compared statistical methods that combine VF and OCT measurements with the method used in routine practice (the reference method), which is based only on VF measurements. We aimed to establish the relative ability of the methods to identify worsening (enlarging or deepening areas of vision loss) in eyes at risk, while ensuring that most stable eyes were not flagged as worsening. We also measured the time taken to identify worsening, the accuracy of the rate of worsening measurements and the ability, in a clinical trial, of methods to distinguish eyes on treatment from those not on treatment.

We found that a method that combines VF and OCT measurements identified more patients as worsening than the reference method, and it identified worsening sooner. This method was also more accurate than methods based only on the VF in measuring the rate of worsening. However, methods combining VF and OCT measurements were not better at distinguishing eyes on treatment from those not on treatment.

The results suggest that combining measurements would be helpful for detecting worsening sooner in clinical practice, but not yet for evaluating treatment effects in clinical trials.

Optical coherence tomography technology is rapidly advancing and newer OCT technologies may be more advantageous.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Garway-Heath *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.236

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/129/245. The contractual start date was in December 2013. The draft report began editorial review in June 2017 and was accepted for publication in October 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Garway-Heath *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Health Technology Assessment Editor-in-Chief

Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk